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ABSTRACT
A principal mechanism of calcium-mediated neuronal injury is the activation of neutral proteases
known as calpains. Proteolytic substrates for calpain include receptor and cytoskeletal proteins, sig-
nal transduction enzymes and transcription factors. Recently, calpain inhibitors have been shown
to provide benefit in rat models of focal head injury and focal cerebral ischemia. The present study
sought to investigate, in experiment 1, the time course of calpain-mediated cytoskeletal injury in a
mouse model of diffuse head injury by measuring the 150- and 145-kDa a-spectrin breakdown prod-
ucts (SBDP). Secondly, in experiment 2, we examined the effect of early (20 min postinjury) ad-
ministration of the novel calpain inhibitor SJA6017 on functional outcome measured 24 h follow-
ing injury and its effect on posttraumatic a-spectrin degradation. Lastly, in experiment 3, we
examined the effect of delayed (4 or 6 h postinjury) administration of SJA6017 on 24-h postinjury
functional outcome. In experiment 1, isoflurane-anesthetized male CF-1 mice (18–22 g) were sub-
jected to a 750 g-cm weight drop–induced injury and were sacrificed for SBDP analysis at postin-
jury times of 30 min, and 1, 2, 6, 24 and 48 h (plus sham). In experiments 2 and 3, mice were in-
jured as described, and delivered a single tail vein injection of either SJA6017 (0.3, 1, or 3 mg/kg)
or vehicle (administered immediately, 4 or 6 h postinjury [3 mg/kg]). Functional outcome was eval-
uated in both studies , and, in experiment 2, 24-h postinjury assessment of SBDPs was determined.
Following injury, the level of SBDP 145 was significantly different from sham at 24 and 48 h in cor-
tical and at 24 h in the hippocampal tissues and at 48 h in the striatum. Immediate postinjury ad-
ministration of SJA6017 resulted in a dose-related improvement in 24-h functional outcome (p ,
0.05 at 3 mg/kg). Significance was maintained after a 4-h delay of the 3 mg/kg, but was lost after a
6-h delay. Despite improvement in functional outcome at 24 h, SJA6017 did not reduce spectrin
breakdown in cortical or hippocampal tissues. These results support a role for calpain-mediated
neuronal injury and the potential for a practical therapeutic window for calpain inhibition follow-
ing traumatic brain injury. However, measurements of regional spectrin degradation may not be
the most sensitive marker for determining the effects of calpain inhibition.
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INTRODUCTION 
DISRUPTION of intracellular calcium homeostasis is akey constituent in the pathophysiology of traumatic
or ischemic brain injury. Following an injurious event,
there is a massive posttraumatic calcium influx secondary
to glutamate release and opening of glutamate receptor-
associated and voltage-dependent calcium channels (for
review, see McIntosh et al., 1997). Excessive intracellu-
lar calcium accumulation can lead to neuronal degener-
ation by (1) activation of various enzymes including 
proteases, kinases, phosphatases, and phospholipases
(McIntosh et al., 1997; Siesjo et al., 1989, Verity, 1992),
(2) induction of free radical release (Hall, 1998; Kontos,
1989), and (3) by mediating detrimental changes in gene
expression (Bading et al., 1993; Rink et al., 1995). Evi-
dence of increased calcium concentrations in models of
traumatic brain injury (TBI) has been demonstrated by
multiple laboratories (Fineman et al., 1993; Nadler et al.,
1995; Nilsson et al., 1993; Shapira et al., 1989).
A principal mechanism of calcium-mediated neuronal
injury is the activation of the neutral proteases known as
calpains (Bartus, 1997; Kampfl et al., 1997). There are
six distinct members of the calpain family, which can be
divided into two groups—calpains that are tissue-specific
and calpains that are ubiquitously expressed (Sorimachi
et al., 1994). The two most recognized isoforms of cal-
pain, m-calpain and m-calpain, require mM and mM con-
centrations of calcium, respectively, for activation in
vitro. However, in vivo activation of both may occur at
much lower calcium concentrations (Coolican et al.,
1984; Nixon, 1989; Suzuki et al., 1990). Identified pro-
teolytic substrates of calpain include receptor proteins
(EGF, IP3, and estrogen receptors), calmodulin-binding
proteins (G proteins, calcineurin), cytoskeletal proteins
(a-spectrin, microtubule-associated protein 2, neurofila-
ments, tau), signal transduction enzymes (phospholipase
C, protein kinase C, tyrosine phosphatase IIb), and tran-
scription factors (c-fos, c-jun, c-myc; for reviews, see
Yuen et al., 1996; Kampfl et al., 1997).
Perhaps the most studied target for calpain-mediated
injury is the cytoskeleton. Indeed, several laboratories
have shown that degradation of cytoskeletal proteins oc-
curs in experimental models of stroke (Aronowski et al.,
1999; Hong et al., 1994; Liebetrau et al., 1999; Roberts-
Lewis et al., 1994), TBI (Buki et al., 1999; Kampf et al.,
1996; Newcomb et al., 1997; Posmantur et al., 1996;
Saatman et al., 1996a), spinal cord injury (Banik et al.,
1997; Braughler and Hall, 1984; Ray et al., 1999), and
experimental allergic encephalomyelitis (EAE), a model
of the demyelinating disease, multiple sclerosis (for re-
view, see Shields and Banik, 1999). While damage to cy-
toskeletal proteins (e.g., neurofilaments, microtubule-as-
sociated protein, a-spectrin) is evident within the first
minutes following experimental TBI, the height of pro-
teolytic activity appears to occur several hours after in-
jury (Newcomb et al., 1997; Posmantur et al., 1994), and
in the case of mild injury, occurs as late as several days
(Saatman et al., 1998). This delayed and long sustained
(Saatman et al., 1996a) degradation of the cytoskeleton
may provide a practical therapeutic window for pharma-
cological calpain inhibition beyond the early moments
after TBI.
Several pharmacological inhibitors of calpain have
been identified including leupeptin, antipain, calpain in-
hibitor I and II, calpeptin, E64, AK295, MDL 28170, and
PD150606 (an alpha-mercaptoacrylic acid derivative;
Wang et al., 1996; for reviews, see Wang and Yuen, 1994,
1998; Yuen and Wang, 1996, 1998). The approach of cal-
pain inhibition as a neuroprotective strategy has been val-
idated based on the reported efficacy of calpain inhibitor
II (Posmantur et al., 1997a), AK295 (Bartus et al., 1994;
Saatman et al., 1996a,b), and MDL 28170 (Li et al., 1998;
Markgraf et al., 1998) in models of traumatic and is-
chemic brain injury. In the case of MDL 28170, it has
been reported to reduce infarct size in rats subjected to
temporary middle cerebral artery occlusion even when
administered 6 h after onset of ischemia (Markgraf et al.,
1998). However, the therapeutic window for calpain in-
hibition in TBI models has not been reported.
More recently, a new reversible peptide aldehyde in-
hibitor of calpain, SJA6017 (Fig. 1), has been introduced
(Fukiage et al., 1997). SJA6017 is similar in many ways
to others of it’s class (MDL 28170, calpain inhibitor I
and II), yet, based on unpublished data, perhaps less cy-
totoxic than the MDL 28170 compound. For example, in
a human neuroblastoma SH-SY5Y cell based assay
which measures lactate dehydrogenase (LDH) release as
a measure of cell toxicity (Posmantur et al., 1997b), the
50% lethal concentration (LC50) for SJA6017 was .500
mM compared to 74 mM for MDL 28170. Similar results
were also seen in a rat cerebellar granular neuron based
assay (Nath et al., 1998) where the LC50 for SJA6017
was .500 mM compared to 100 mM for MDL 28170
(K.K.W. Wang, R. Nath, and M. Fields, unpublished
data).
The presently reported study involved an examination
of SJA6017 using a mouse model of moderately severe,
diffuse head injury (Hall et al., 1995; Fig. 2). To our
knowledge, this is the first time a calpain inhibitor has
been studied in a model of diffuse traumatic brain injury,
as well as the first to employ mice. Previous studies have
been conducted in rat models of focal injury such as con-
trolled cortical impact (Kampfl et al., 1996, 1997; Pos-
mantur et al., 1997a) or in temporal fluid percussion
(Saatman et al., 1996b; 2000). The design of our study
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sought first to establish a time course of calpain-medi-
ated cytoskeletal degradation by measuring a-spectrin
breakdown over the first 48 h postinjury. a-Spectrin is a
280-kDa nonerythroid cytoskeletal protein that provides
structural support to membranes. It is also a substrate for
calpain, which can cleave a-spectrin at tyrosine 1176 to
yield a 150-kDa fragment (SBDP150) or at glycine 1230
to yield a 145-kDa fragment (SBDP145; Harris and Mor-
row, 1988). The second aim was to establish a dose-re-
sponse analysis of early (20 min postinjury) administra-
tion of SJA6017 in terms of improvement in 24-h
behavioral response. After definition of a dose that pro-
moted improved functional outcome, the effect of
SJA6017 on posttraumatic a-spectrin degradation was
examined. The third aim was to evaluate the therapeutic,
posttraumatic, time window by examining the efficacy of
delayed (4 or 6 h postinjury) administration of SJA6017.
MATERIALS AND METHODS
All procedures were carried out in strict compliance
with the Institutional Animal Care and Use Committee
of Parke-Davis Pharmaceutical Research.
Mouse Model of Diffuse Head Injury
The mouse head injury method was first introduced by
Hall et al. (1995) and was employed as described previ-
ously except for the addition of an anesthetic component.
Male CF-1 mice (Charles River, Portage, MI), weighing
17–21 g, were fed ad libitum prior to injury. Mice were
briefly anesthetized in a chamber containing 2.5% isoflu-
rane (Anaquest) balanced with air and oxygen. Each
mouse was grasped by the dorsal skin of the neck, and
its head placed upon the base of the injury device. A
round, flat, 6-mm diameter Teflon impounder was posi-
tioned firmly against the top of the head, centered be-
tween the ears and eyes, and a 50-g stainless steel weight
was released at a height of 15 cm, producing a velocity
calculated at 171.5 cm/sec. The resulting moderately se-
vere injury creates a pattern of diffuse degeneration,
which is diversely projected into the brain with variable
intensity (Fig. 2). To prevent posttraumatic hypothermia,
injured mice were placed in a Hova-Bator incubator
(model 1583, Randall Burkey Co.) at 37ºC until con-
sciousness was regained (20–30 min).
Experimental Design
Three separate experiments were performed. Experi-
ment 1 measured a-spectrin degradation in cortex, hip-
pocampus and striatum over a 48-h postinjury time
course. Experiment 2 examined the dose-response for the
effect of immediate postinjury administration of SJA6017
on functional recovery and a-spectrin degradation mea-
sured 24 h following injury. Experiment 3 looked at the
effect of delayed administration of SJA6017 on func-
tional recovery measured 24 h following injury.
Western Immunoblotting of a-Spectrin
Degradation Products
In experiment 1 and 2, spectrin degradation was quan-
tified by Western immunoblots as previously described
(Nath et al., 1996), and expressed as the ratio of 150- or
145-kDa spectrin fragment to intact spectrin. The mice
were deeply anesthesia with isoflurane, killed and their
brains immediately removed and briefly rinsed in chilled
saline (0.9% sodium chloride for irrigation, USP). Tis-
sues from each brain, representing cortex, striatum and
hippocampus, were dissected on a chilled stage and then
frozen in ice cold isopentane (240°C) and stored at
280°C. Frozen brain tissue was powdered with pre-
cooled mortar-pestle over dry ice. Approximately 50 mg
of powdered tissue was resuspended in triton lysis buffer
[1 % triton, 20 mM TrisHCL, 150 mM NaCl, 5 mM
EDTA, 1 mM DTT and protease inhibitor cocktail
(Boehringer Mannheim)]. The samples were placed on
ice for 5 min with intermittent vortexing. The lysate was
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FIG. 1. Chemical structure of the calpain inhibitor SJA6017
and 50% inhibitory concentration (IC50) activity levels in rele-
vant assays. IC50 assay for SBDP 150 and SBDP 145 was done
in triplicate using Molt-4 (human leukemic) cells that were
preincubated 1 h with varying concentrations of SJA6017. En-
dogeneous calpain was activated by addition of the calcium
ionophore A23187, and, following incubation, the proteins were
extracted and concentrations were determined. Protein samples
were run on SDS/PAGE and transferred onto PVDF mem-
branes, which were probed with anti–a-spectrin antibody
(Chemicon), followed by a standard development protocol.
Densitometric analysis of the 150- and 145-kDa bands were
preformed with the NIH program Image 1.5; mean values were
plotted and the concentration of SJA6017 that reduced the in-
tensity of the 150- and 145-kDa bands by 50% was determined.
(§Assays referenced in Wang et al., 1996).
cleared by centrifugation at 20,000-3 g for 15 min at
4°C. Protein concentration in the cleared lysate was de-
termined using a modified Lowry assay (Bio-Rad). Each
lane was loaded with 20 mg of protein and run on
SDS/PAGE [4–20% (w/v) acrylamide] with Tris/glycine
running buffer system and then transferred to a nitrocel-
lulose membrane using a semi-dry electrotransferring
unit (Bio-Rad) at 20 mA for 2 h. The blots were probed
with an anti-a-spectrin antibody (monoclonal, Affi Labs,
U.K.) and developed in a linear range using nitro blue
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate.
Densitometric analysis of Western blots was done using
a color scanner (Umax UC630) and the NIH program,
Image 1.5.
Western blot data are expressed as mean 6 SE. Injury-
induced increases in the ratio of SBDP 150 or 145/intact
spectrin were compared to control animals using a one-
way ANOVA followed by a Bonferroni Multiple Com-
parisons test for selected pairs. A p value of 0.05 com-
pared to sham was considered significant.
SJA6017 Administration
In experiment 2, beginning approximately 20 min post-
TBI, 17–18 mice each were randomly assigned to one of
four groups, each receiving a single tail-vein injection of
SJA6017 at 0.3, 1, or 3 mg/kg or vehicle. SJA 6017 was
dissolved in 88% propylene glycol, 10% ethyl alcohol,
and 2% benzyl alcohol at varying concentrations to ac-
commodate a dosing volume of 0.05 mL per animal. In
experiment 3, beginning 4 or 6 h post-TBI, 15 mice each
were randomly assigned to one of two groups, each re-
ceiving a single tail-vein injection of either SJA 6017 (3
mg/kg; 60 mg/mL/kg; 0.05 mL per injection) or vehicle.
SJA 6017 was prepared as described in experiment 2.
Assessment of Functional Outcome
In experiment 2 and 3, functional outcome was as-
sessed by means of a previously described grip score
(Hall, 1995) with modifications. Briefly, at 24 h post-
TBI, the mice were suspended by their tails and their
forepaws were placed in contact with a taut string
stretched 40 cm above a padded surface. Once the
forepaws were in contact, the tails were released and the
mice were evaluated for (1) length of time they remained
on the string (with a 30-sec maximum) and (2) their per-
formance while on the string. Both measurements were
tallied and then combined into a single grip score, with
a total score of 6 representing the best measurable out-
come (Table 1).
In experiment 2 and 3, data are expressed as mean 6
SE. Grip scores were compared, in study 1, by Kruskal
Wallis nonparametric ANOVA and posthoc Mann-Whit-
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FIG. 2. Sample time course of diffuse neuronal degeneration in male mice following diffuse head injury as measured by amino-
cupric silver staining (shown in black), a marker for neuronal degeneration and debris (Fix et al., 1996; de Olmes et al., 1994;
Switzer, 2000). Neurohistology was performed by NeuroScience Associates (Knoxville, TN). Brains were embedded together in
a single block of geletin, freeze sectioned at 35 mM, and stained for degeneration using the amino cupric silver method of de Ol-
mos et al., 1994) and counterstained with neutral red to reveal normal cell bodies. The resulting, moderately severe, injury cre-
ates a pattern of diffuse degeneration, which is diversely projected into the brain with variable intensity. The progression and de-
gree of neuronal degeneration appears to occur over a number of days following TBI.
ney test (Fig. 5A). An analysis of mice exhibiting the best
measurable outcome score compared to those of partial
scores was measured by x2 for trend (Fig. 5B). In ex-
periment 3, grip scores were compared by a Mann-Whit-
ney test (Fig. 7A), and an analysis of mice exhibiting the
best measurable outcome score compared to those of par-
tial scores was measured by Fisher’s exact test (Fig. 7B).
RESULTS
Time Course of a-Spectrin Degradation
Following Traumatic Brain Injury
The time course of cortical a-spectrin breakdown (gen-
eration of SBDP150 and SBDP145) in mice subjected to
diffuse head injury is demonstrated by Western 
immunoblot in Figure 3. The SBDP150 and SBDP145
bands were densitometrically measured and then nor-
malized to intact a-spectrin (280 kD level), shown in Fig-
ure 4. Cortical levels of SBDP 145 were significantly dif-
ferent than sham at 24 and 48 h postinjury. Significant
SBDP 145 increases in the striatum were present only at
24 h postinjury, while hippocampal levels of SBDP 145
reached significance by 48 h following injury. Although
a similar trend towards time course increases in SBDP
150 for the three different brain regions can be appreci-
ated, there were no significant differences in SBDP 150
levels in cortex, striatum, or hippocampus.
Effect of Immediate Postinjury Administration of
SJA6017 on Functional Outcome
Figure 5A illustrates the dose-response effect of
SJA6017 on functional outcome at 24 h following injury
in mice that received an immediate, postinjury, tail-vein
injection of SJA6017. Functional outcome was enhanced
in a dose-dependent manner, with a significant improve-
ment in grip score seen at the 3 mg/kg dose (nonpara-
metric ANOVA Kruskal-Wallis, p 5 0.0475; Mann-
Whitney test compared to sham, p , 0.05). Similarly,
drug-treated mice displayed a dose-dependent increase in
the incidence of “best outcome” scores when compared
to vehicle-treated mice (x2, p 5 0.0024; Fig. 5B).
Effect of SJA6017 on Posttraumatic a-Spectrin
Degradation
Cortical and hippocampal tissues were harvested for
measurement of SBDPs at 24 h postinjury from the brains
of mice receiving 3 mg/kg of SJA6017 in the dose re-
sponse study (Fig. 5). Striatal tissues were not evaluated,
based upon time course data indicating low SBDP levels
24 h following injury (Fig. 4). Figure 6 is a summary of
Western immunoblots that were densitometrically mea-
sured and normalized to intact a-spectrin (280-kD level).
Despite a beneficial effect on functional outcome,
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TABLE 1. GRIP SCORE SCALE FOR THE MEASUREMENT OF
FUNCTIONAL OUTCOME IN MICE FOLLOWING TBI
Time score
0 5 unable to hold onto string
1 5 hold onto string 1–10 sec
2 5 holds onto string 11–20 sec
3 5 holds onto string 21–30 sec
Performance score
0 5 unable to hold onto string
1 5 holds on, but unable to bring hind limb(s) to string
2 5 holds on and draws hind limb(s) to string
3 5 holds on and able to move along string
Time and performance scores for each mouse were combined
into a single grip score with a combination of six representing
highest measurable outcome.
FIG. 3. Western immunoblots showing the time course of a-
spectrin breakdown products, SBDP150 and SBDP145, in the
mouse cortex following TBI. Intact a-spectrin is represented by
the 280-kD band (n 5 4 mice/group).
SJA6017 did not attenuate the levels of SBDPs in corti-
cal or hippocampal tissue.
Effect of Delayed Postinjury Administration of
SJA6017 on Functional Outcome
Twenty-four hours following head injury, mice that re-
ceived a 4-h postinjury dose of 3 mg/kg SJA6017, had
significant improvement in functional outcome compared
to vehicle-treated mice (Mann-Whitney test, p , 0.05;
Fig. 7A). The incidence of a head-injured mouse receiv-
ing a score of best outcome was 4.5 times greater in the
drug treated mice than in time-matched, vehicle-treated
mice (Fisher’s Exact test, p , 0.01; Fig. 7B). However,
both of these effects were lost when SJA6017 was with-
held until 6 h postinjury (Fig. 7A,B).
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FIG. 4. Summary graph of the Western immunoblot time course of SBDP150 (A) and SBDP145 (B) in the mouse hippocampus,
striatum, and cortex following TBI (mean 6 SE). Data is densitometrically measured and expressed as a ratio of SBDP/intact a-
spectrin (280 kD). *p , 0.05 compared to sham (n 5 4 mice/group). 
DISCUSSION
The approach of calpain inhibition as a therapeutic
strategy for traumatic brain injury is based, in large part,
upon the desire to impede the occurrence of delayed ax-
onal injury resulting from the calcium-mediated cascade
of events following an injurious insult to the brain (Buki
et al., 1999; Povlishock et al., 1999). Calcium-mediated
cytoskeletal damage can lead to disruption in axonal
transport, structural collapse and subsequent retrograde
neuronal cell death. However, calpain activation and cy-
toskeletal degradation also occurs in neuronal cell bod-
ies and dendrites. In either event, antibodies recognizing
the breakdown products of (a-spectrin, a substrate for
calpain-mediated proteolysis, have been used as a tool to
identify cytoskeletal damage associated with calpain ac-
tivation (Kampfl et al., 1996; Posmantur et al., 1997a;
Roberts-Lewis and Siman, 1993). In models of focal
brain injury, these antibodies have been employed to es-
tablish the early presence of SBDP in areas of primary
tissue injury and, at later postinjury time points, have also
provided evidence for SBDP in areas of the brain distal
from primary focal insult (Saatman et al., 1996a).
Utilizing a model of diffuse brain injury, we, too, re-
port significant increases in SBDP, but only at time points
beginning 24–48 h postinjury, likened to the later, sec-
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FIG. 5. (A) Dose response curve showing the ability of immediate postinjury administration of SJA6017 to improve functional
outcome in mice 24 h following TBI (nonparametric ANOVA, p 5 0.0475, mean 6 SE). *Posthoc test, p , 0.05 compared to
sham (n 5 17–18 mice/group). (B) Graph of a contingency table analysis indicating the number of mice in each treatment group
exhibiting the best outcome score against those of partial scores (x2 for trend, p 5 0.0024).
ondary phase of calpain-mediated spectrin proteolysis
seen in focal brain injury models. Povlishock and col-
leagues (Buki et al., 1999), employing a similar model
of diffuse brain injury in rats, have provided compelling
evidence (via ultrastructural, immunohistochemical ex-
amination with antibodies to SBDP and RMO-14, a
marker for neurofilament compaction) for delayed, pro-
gressive calpain-mediated spectrin proteolysis. In the
clinical setting, there is also evidence to support sec-
ondary axonal injury, which is believed to occur over a
period of 12 or more hours (Blumbergs et al., 1995;
Christman et al., 1994; Gentleman et al., 1993; Grady et
al., 1993). McCracken and colleagues (McCracken et al.,
1999) have recently described SBDPs and neurofilament
protein degradation in the corpus callosum of patients
suffering blunt head injury at time points greater than 24
h following injury (compared to control subjects), fur-
thering the suggestion that calpain-mediated damage to
the cytoskeleton is a likely contributor to axonal injury
in human head trauma. The reported efficacy of SJA6017
in our present study is believed to be the first demon-
stration of a calpain inhibitor having beneficial effects in
a primarily diffuse injury paradigm. Significant im-
provement in functional outcome was demonstrated fol-
lowing immediate post-injury administration, as well as
after a 4-h delay in treatment. This type of therapeutic
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FIG. 6. Summary graph of Western immunoblots measuring SBDP150 and SBDP145 in TBI mouse cortex (A) and hippocampus
(B) 24 h after receiving 3 mg/kg of SJA6017 immediately postinjury (mean 6 SE). Data is densitometrically measured and ex-
pressed as a ratio of SBDP/intact a-spectrin (280 kD; n 5 13 mice/group).
window has been demonstrated in a model of focal cere-
bral ischemia where 6-h delayed administration of the
calpain inhibitor MDL 28170 was shown to be protec-
tive (Markgraf et al., 1998).
Interestingly, the beneficial behavioral effects of
SJA6017, measured 24 h postinjury, were not accompa-
nied by a quantifiable effect on a-spectrin degradation in
cortical and hippocampal regions. a-Spectrin degradation
was equal for both treated and untreated brain-injured
mice, despite significantly different behavioral outcome
profiles for the same two treatment groups. One possible
explanation for not seeing lower levels of SBDPs in the
TBI mice receiving SJA6017 might be that the 24 h
postinjury time point chosen may not be the most sensi-
tive for seeing significant differences in SBDPs. It may
be that postinjury time points of 48 h or later may pro-
vide better reflections of calpain inhibition. An additional
issue to consider is the choice of brain regions in which
SBDPs were measured. Because of the diffuse and un-
even nature of neuronal degeneration in the cortex, hip-
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FIG. 7. (A) Graph showing improved functional outcome 24 h following TBI in mice receiving a 4-h delayed, postinjury, tail-
vein injection of SJA6017 (3 mg/kg), but no improvement in outcome following a 6-h delayed administration of SJA6017 (mean 6
SE). *p , 0.05 compared to time-matched vehicle control (n 5 15–16 mice/group). (B) Graph of a contingency table analysis
indicating the number of mice in each treatment group exhibiting the best outcome score against those of partial scores. *p ,
0.05 between the 4-h delayed vehicle and drug-treated groups (Fisher’s exact test).
pocampus and striatum in our model, the western im-
munoblot analysis of calpain-mediated cytoskeletal dam-
age may not be sensitive enough to detect the early in-
hibition of a-spectrin degradation when measured in
large portions of these brain regions. In other words, drug
effects on axonal cytoskeletal preservation may be sim-
ply diluted out.
The lack of effect of SJA6017 on SBDP inhibition at
doses that promote functional improvement is not un-
precedented. Saatman and colleagues have recently
demonstrated a similar finding with the calpain inhibitor
AK295 (Saatman et al., 2000). While AK295 was previ-
ously shown to attenuate motor and cognitive deficits fol-
lowing lateral fluid percussion brain injury in rats (Saat-
man et al., 1996b), in separately treated animals, there was
no evidence that doses of AK295 which enhanced be-
havioral recovery could reduce calpain-mediated spectrin
proteolysis or overt cortical damage (Saatman et al.,
2000). These investigators have postulated that this lack
of quantifiable SBDP effect, despite positive functional
outcome, might be due to multiple explanations. First of
all, calpain inhibition may be occurring in regions within
the brain that were beyond the capacity of their present
study. Secondly, because calpain plays a role in many in-
tracellular events, it is quite possible that the behavioral
efficacy noted might be a result of the protection of cal-
pain proteolytic substrates other than the more commonly
measured cytoskeletal break down products. These alter-
native targets for calpain include receptor and calcium-
binding proteins, signal transduction enzymes and/or tran-
scription factors (Kampfl et al., 1997; Yuen et al., 1996).
As a final point, it should be noted that caspase 3 ac-
tivation, in addition to that of calpain, can contribute to
(a-spectrin proteolysis, although caspase 3 activity only
generates the 150-, but not the 145-kD band (Wang et
al., 2000). Thus, in the case of the time-related increase
in the 150-kD SBDP, caspase 3 and calpain may both
play a degradative role. However, by 24-h, at which time
our behavioral outcome assessment was made, the in-
crease in the 145-kD SBDP is quantitatively much more
convincing than that of the 150-kD fragment. Therefore,
at least during the first 24 h postinjury, it seems likely
that calpain activation is quantitatively more important
than caspase 3. Moreover, SJA6017 does not inhibit cas-
pase 3 or, for that matter, caspase 1 (i.e., interleukin-con-
verting enzyme; a.k.a. ICE), and it does not possess any
hypothermic effects (Senju Pharmaceuticals, Ltd., un-
published data). These facts, taken together, strongly sup-
port the conclusion that the beneficial effects of SJA6017
on 24-h behavioral outcome are, almost certainly, related
to calpain inhibition, despite the lack of a demonstrable
decrease in posttraumatic spectrin degradation at that
time point.
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